Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zhengye Biotechnology Holding (ZYBT) Total Non-Current Liabilities (2023 - 2025)

Historic Total Non-Current Liabilities for Zhengye Biotechnology Holding (ZYBT) over the last 3 years, with Q2 2025 value amounting to $649787.9.

  • Zhengye Biotechnology Holding's Total Non-Current Liabilities changed N/A to $649787.9 in Q2 2025 from the same period last year, while for Jun 2025 it was $649787.9, marking a year-over-year change of. This contributed to the annual value of $668018.0 for FY2024, which is 5453.24% down from last year.
  • Per Zhengye Biotechnology Holding's latest filing, its Total Non-Current Liabilities stood at $649787.9 for Q2 2025.
  • In the past 5 years, Zhengye Biotechnology Holding's Total Non-Current Liabilities registered a high of $1.4 million during Q4 2023, and its lowest value of $649787.9 during Q2 2025.
  • For the 3-year period, Zhengye Biotechnology Holding's Total Non-Current Liabilities averaged around $920030.4, with its median value being $668235.4 (2024).
  • Within the past 5 years, the most significant YoY rise in Zhengye Biotechnology Holding's Total Non-Current Liabilities was 5366.13% (2024), while the steepest drop was 5366.13% (2024).
  • Over the past 3 years, Zhengye Biotechnology Holding's Total Non-Current Liabilities (Quarter) stood at $1.4 million in 2023, then plummeted by 53.66% to $668235.4 in 2024, then decreased by 2.76% to $649787.9 in 2025.
  • Its last three reported values are $649787.9 in Q2 2025, $668235.4 for Q4 2024, and $1.4 million during Q4 2023.